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Genomics SelectGWAS: ‘‘G-whiz!’’ or ‘‘GWAShed-up’’? Genome-wide association studies (GWASs) link single-nucleotide variations in the
human genome to a complex trait. Over the past 4 years, these ground-breaking studies have identified almost 1000
alleles increasing an individual’s risk for developing common diseases, such as cancer and obesity. However, these vari-
ants often explain only a small portion of the heritability of most complex traits. This Genomics Select highlights recent
studies suggesting two specific strategies for finding this ‘‘missing heritability’’: increasing the statistical power of
GWASs and characterizing rare structural variations in the human genome not traditionally explored by GWASs.Digging Deep for Diabetes Genes
Type 2 diabetes afflicts7% of Americans and150 million individuals worldwide. In the simplest case, GWASs would have
located 10–20 single-nucleotide polymorphisms (SNPs) in the human genome, with each one contributing 5%–10% of the
heritability of type 2 diabetes. Instead, however, eight previousGWASs identified 25 common variations that together account
for less than 10% of the overall genetic contribution to this chronic illness. Where is the remaining 90%? One explanation for
themissing heritability is that the statistical power of GWASs is too low to detect common alleles that contribute only minutely
to a disease. Now, Voight et al. (2010) demonstrate that a valuable strategy for improving the statistical power of GWASs is to
combine the results of previous experiments into one largemeta-analysis. Indeed, bymerging the data from the previous eight
GWASs, the authors identify 12 new polymorphisms linked to type 2 diabetes and increase the total number of disease loci by
awhopping 50%.Moreover, these newpolymorphisms include the first association of type 2 diabetes with the X chromosome
and seven loci that overlap with regions already connected to other phenotypes, such as basal cell carcinoma and high
cholesterol. To characterize the physiological relevance of all 38 common variants linked to type 2 diabetes, Voight et al.
correlated the genotype data with clinical observations. Ten loci were associated with reduced function of the pancreatic
beta cells that produce insulin, whereas three loci were correlated with reduced insulin sensitivity. Although the polymor-
phisms identified in the study do not illuminate the specific genes and molecular processes underlying an individual’s risk
for developing type 2 diabetes, these results do pinpoint promising hotspots in the genome where such information lies.
Future sequencing and fine-mapping of these regions will hopefully light the path to stopping this growing worldwide
epidemic.
B.F. Voight et al. (2010). Nat. Genet. 42, 579–589.Genetic factors determine 80% of height varia-
tion among humans. Cartoon by K. Mahan.Working Together, SNPs Reach New Heights
If pooling data frommultiple studies increases the power of GWASs to detect
risk alleles, could pooling the polymorphisms increase the heritability
accounted for by common variants? Conventional GWASs calculate how
much each allele individually contributes to the total variation in a given
phenotype (i.e., its effect size). If the effect of a polymorphism is below a
statistical threshold, then the variant is dismissed as insignificant and over-
looked as a player in the etiology of the disease. However, if these small
contributors are analyzed together, their total impact on a given phenotype
may be large enough to pass even very stringent statistical tests typically
used in GWASs. Indeed, Yang et al. (2010) report that for human height,
a big chunk of the ‘‘genetic dark matter’’ is hidden in a slew of common vari-
ants that never reached statistical significance in previous GWASs (i.e., false
negatives). Three previous GWASs with more than 10,000 individuals identi-
fied50 common variants associated with height, but these polymorphisms
accounted for only 6% of height heritability. In contrast, when Yang et al.
simultaneously fit all of the common polymorphisms, which included
295,000 SNPs, they find that together these common alleles explain
56% of the genetic factors contributing to height. So what about the other
44%? A series of calculations and simulations suggest that this discrepancy
may be largely because polymorphisms genotyped in GWASs and the nucle-
otide variations that actually determine a person’s height are not always inherited together. When they take this ‘‘incomplete
linkage disequilibrium’’ into account, the common polymorphisms identified by GWASs explain almost 67% of height herita-
bility. Could the remaining genetic factors arise from rare structural variations in the human genome that are not correlated
with GWAS SNPs?
J. Yang et al. (2010). Nat. Genet. 42, 565–569.Cell 142, July 23, 2010 ª2010 Elsevier Inc. 177
A functional map of autism spectrum disorder.
Image courtesy of D. Pinto and S.W. Scherer.Think Structure, Not Sequence
Although conventional GWASs focus only on single-nucleotide differences
between individuals, a hefty portion of the diversity in the human genome
originates from structural variations in which entire genes or genomic
regions are deleted, duplicated, or rearranged. Now, Pinto et al. (2010)
present evidence that these so-called ‘‘copy-number variants’’ (CNVs) may
account for a substantial amount of the heritability underlying autism spec-
trumdisorder, a condition characterized by abnormal social interactions and
sometimes cognitive dysfunction. Moreover, the authors use these rare
structural variations to generate the first functional map of biological path-
ways potentially disrupted in autistic individuals. Genetics plays a key role
in autism spectrum disorder, but previous GWASs identified only two
common polymorphisms associated with a small increased risk for the
disease. To uncover rare structural variations linked with autism, Pintoet al. scanned the genome of 996 individuals with autism and used microarrays to compare their CNVs with those of their
parents and 1300 controls. With new algorithms and stringent ‘‘quality control’’ criteria, Pinto et al. pinpointed 5500
rare CNVs R30 kb in size that occurred with a frequency of <1%. Although the total number of these structural variations
per person is the same across all three groups, individuals with autism surprisingly carry 26%more gene deletions (or partially
gene deletions) than their parents and the controls. Each specific deletion is quite rare, appearing in only a few patients;
however, the genes disrupted often function in similar biological pathways, including those involved with intellectual disabil-
ities. For example, many of the gene deletions affect neuronal development, proliferation, motility, and signaling by GTPase/
Ras components. These results suggest that each person with autism likely carries his own unique set of ‘‘autism’’ loci;
however, the biological processes impacted by these genomic rearrangements will probably be similar for many individuals.
D. Pinto et al. (2010). Nature. Published online June 9, 2010. 10.1038/nature09146.Rearranging Our View on Gene Dosage
In contrast to autism spectrum disorder, for which no single gene or even a specific group of genes usually underlies the
disease, the genetic origins of Charcot-Marie-Tooth disease type 1A and HNPP (hereditary neuropathy with liability to pres-
sure palsies) are relatively clear. Either a duplication or a deletion of a 1.4 Mb segment near the gene encoding peripheral
myelin protein (PMP22) leads to these incurable nerve disorders. Now, a study by Zhang et al. (2010) shows that, even in rela-
tively clear-cut cases such as these, an unexpectedly diverse array of rare genomic rearrangements can cause the same
disease. Moreover, these rare structural variations do not need to occur within PMP22 to alter its expression and cause
neuropathy. Using a genomic hybridization technique in combination with high-resolution microarrays, Zhang et al. identified
17 unique structural variations within or near the PMP22 gene from 21 patients with Charcot-Marie-Tooth disease type 1A or
HNPP. Half of these rare genomic rearrangements did not alter the integrity of the PMP22 gene but instead changed its total
copy number by deleting, duplicating, or even triplicating the PMP22 gene. Interestingly, one patient possessed a duplication
of a 194 kb segment upstream of the PMP22 coding region. The diverse size, location, and content of the structural variations
uncovered for even this tiny section of the genome underscores the daunting challenge in identifying rare variations in copy
number for genome-wide studies on complex diseases.
F. Zhang et al. (2010). Am. J. Hum. Genet. 86, 892–903.Heritability Hide-and-Seek
Taken together, the four articles highlighted in this Select suggest that for certain diseases and phenotypes, the heritability is not
‘‘missing’’ but simply hiding below the statistical threshold of standard GWASs. In contrast, for other traits, a large portion of the
heritability resides in rare structural variations—similar to those described forCharcot-Marie-Tooth disease and autismspectrum
disorder—that requirenewtechniquesandmethods toobserve.Canwepredictapriori inwhichcategoryadiseaseor traitwill fall?
Enter Park et al. (2010), who use existing GWAS data to estimate the expected number of additional disease loci that future
GWASswill uncover. Furthermore, their statistical method calculates both the sample size required to detect these new variants
and thepower thesealleleshave forpredictingan individual’s risk foradisorder. Forexample, theauthorsestimate that forCrohn’s
disease, 142 additional susceptibility loci are detectable in a GWAS with 25,000 patients and controls. Furthermore, these
commonpolymorphisms togetherwill explain20%of the heritability of this inflammatory bowel disorder. In contrast, for breast,
prostate, and colorectal cancers, Park et al. estimate that only 67 additional loci are required on average to explain17% of the
genetic factors for each cancer. Although these calculations indicate that larger GWASs or meta-analyses will indeed uncover
manymore susceptibility alleles for these complex diseases, the results of this analysis also indicate that >50%of the heritability
will still be ‘‘missing.’’ Thus, at least for most chronic illnesses, the hunt for heritability will continue for many years to come.
J.H. Park et al. (2010). Nat. Genet. 42, 570–575.
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